Investment Thesis
TuHURA is a pre-revenue biotech company in acute financial distress with zero sales, -$27.6M operating cash burn, and only $3.6M cash reserves (sufficient for ~6 weeks of operations). The company faces imminent liquidity crisis with current ratio of 0.78x and cannot cover short-term obligations with current assets, requiring immediate capital infusion to avoid insolvency.
Strengths
- Minimal debt burden (Debt/Equity 0.00x, long-term debt only $265K)
- Positive stockholders' equity of $20.9M provides some asset backing
- Engagement indicated by 5 insider Form 4 filings in last 90 days
Risks
- Zero revenue and no clear path to profitability without successful product launch
- Critical liquidity crisis: current ratio 0.78x with $3.6M cash against $27.6M annual cash burn
- Deeply negative returns: ROE -143.6%, ROA -109.9%, suggesting severe capital inefficiency
- Unsustainable cash burn rate will necessitate dilutive financing or bankruptcy within months
Key Metrics to Watch
- Cash balance and runway (critical near-term survival metric)
- Revenue generation timeline from pipeline assets
- Capital raise announcements and dilution impact on equity
Financial Metrics
Revenue
0.0
Net Income
-30.1M
EPS (Diluted)
$-0.63
Free Cash Flow
-27.7M
Total Assets
27.4M
Cash
3.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-143.6%
ROA
-109.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.78x
Quick Ratio
0.74x
Debt/Equity
0.00x
Debt/Assets
23.5%
Interest Coverage
-48.06x
Long-term Debt
265.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T11:03:21.346087 |
Data as of: 2025-12-31 |
Powered by Claude AI